Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 212.07% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 705.92K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 705.92K.
Overvalued
The company’s latest PE is -1.17, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.64M shares, decreasing 59.12% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 20.76K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.74.